Atopic dermatitis: patent license

We have currently been granted the patent in 30 countries
We are constantly growing


We have currently been granted the patent in 30 countries and are in the process of obtaining the patent in 22 additional countries.

This strain mixture is licensed in more than 20 countries around the world to several renowned international pharmaceutical companies.

If you want to check available territories, contact us.

Atopic dermatitis is a chronic, recurrent and allergic skin disease characterised by intense itching, inflammation, impaired skin barrier function and intermittent outbreaks. It is most prevalent in children (> 20%) but is also found in adults. It is also associated with an increase in other diseases, such as asthma, allergic rhinitis and chronic sinusitis.

The routine treatment is based on the use of topical corticosteroids, which in the long term have limited efficacy and a higher prevalence of side effects, and the use of systemic drugs (oral corticosteroids, immunosuppressants, monoclonal antibodies, etc.), which are more effective, but produce considerable toxic effects and increase the risk of rebound effect after treatment.

Clinical Trial


In seeking safe alternative treatments with probiotics, a double-blind, randomised, placebo-controlled clinical trial was conducted in which the efficacy of a probiotic mixture was evaluated in children and adolescents up to 17 years of age with atopic dermatitis.


The investigational product consisted of one capsule per day containing a mixture of freeze-dried probiotic strains at a concentration of  1×10^9 cfu or a maltodextrin-based placebo capsule, once daily, for 12 weeks.

These research results were published in  Jama Dermatology.


Following evaluation of the results of the 50 patients included in the study, it was observed:

Patients in the probiotic group reduced their SCORAD index (which quantifies the severity of the disease) by up to  77%.

Compared to 22.7% in the placebo group. There was a statistically significant reduction in the intensity and extent of eczema and in corticosteroid use compared to the placebo group.

The results showed the great potential of the probiotic mixture patented by Bioithas as a treatment for atopic dermatitis, which led to the filing of PCT international application WO2018015388 for its use in this pathology worldwide.



    You can also write to us at or call 865 78 01 70.

    All personal data that you submit us via this form will be processed by Data Controller BIOITHAS, S.L. and saved into CONTACTS processing activitie, with the purpose of answering your inquiry, via email or phone, and for a later follow up.

    Processing shall be lawful because you give us your consent for these specific purposes. Your personal data will not be disclosed to third parties unless forced by law. You have right to access to, rectify, or delete your personal data, and other rights as explained in our Privacy Policy:

    Our accreditations

    Innovative SME Seal

    Innovative Technology-Based Enterprise (EIBT) Seal

    BIOITHAS S.L. has been a beneficiary of the European Regional Development Fund.

    A way to make Europe.